A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts
Phase of Trial: Phase IV
Latest Information Update: 11 Feb 2019
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms TRACE
- Sponsors Actelion Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 23 May 2018 Trial design presented at the 114th International Conference of the American Thoracic Society.
- 14 Nov 2017 Planned End Date changed from 28 Dec 2019 to 28 Jun 2019.